ArticleClinical Medicine Insights. Oncology2025
Unveiling HJURP as a Biomarker of Poor Prognosis and Immunotherapy Resistance in Lung Adenocarcinoma: A Multicenter Study.
Article in Clinical Medicine Insights. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is the most common lung cancer, associated with high metastasis and low survival rates. Identifying reliable biomarkers is essential for better prognosis and treatment. Methods: In this study, we analyzed RNA sequencing data, mutation information, and clinical data from the TCGA-LUAD cohort and other multicenter datasets to investigate the role of Holliday junction recognition protein (HJURP) in LUAD. We employed immunohistochemistry in tissue microarray cohort to validate the prognostic significance of HJURP. The DepMap project was used to validate the effect of HJURP knockout in vitro. Results: Holliday junction recognition protein was identified as an adverse prognostic factor in the TCGA-LUAD cohort and diverse ethnic groups. Its expression correlated with poor immunotherapy outcomes, and HJURP knockout suppressed cancer cell proliferation. High HJURP expression was linked to increased mutation frequency, particularly in TP53 and TTN. Pan-cancer analysis also indicated HJURP as a poor prognostic factor in various solid tumors. Conclusions: Holliday junction recognition protein emerges as a significant biomarker in LUAD, consistently associated with poor prognosis across multiple cohorts. Its role in various oncogenic pathways and correlation with advanced disease stages underscore the potential of HJURP as a target for therapeutic intervention and as a marker for prognosis in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.